On Tuesday, H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock.

ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, targeting prostate and lung cancer, but remains in very early clinical stages. Financially, ORIC is well-capitalized for ...

ORIC Pharmaceuticals SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing ...

The last time I wrote an article on ORIC Pharmaceuticals (NASDAQ:ORIC) it was with respect to a Seeking Alpha article entitled "ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that ...